O	0	3	The
O	4	10	effect
O	11	13	of
B-intervention	14	25	transdermal
I-intervention	26	35	estradiol
I-intervention	36	38	or
I-intervention	39	43	oral
I-intervention	44	54	conjugated
I-intervention	55	64	oestrogen
I-intervention	65	68	and
I-intervention	69	80	fenretinide
O	81	87	versus
B-control	88	95	placebo
O	96	98	on
B-condition	99	110	haemostasis
I-condition	111	114	and
I-condition	115	129	cardiovascular
I-condition	130	134	risk
O	135	145	biomarkers
O	146	148	in
O	149	150	a
O	151	161	randomized
O	162	168	breast
O	169	175	cancer
O	176	191	chemoprevention
O	192	197	trial
O	197	198	.

O	199	201	We
O	202	206	have
O	207	217	previously
O	218	226	reported
O	227	230	the
O	231	241	favourable
O	242	248	effect
O	249	251	of
O	252	263	transdermal
O	264	273	estradiol
O	274	275	(
O	275	277	E2
O	277	278	)
O	278	279	,
O	280	288	relative
O	289	291	to
O	292	296	oral
O	297	307	conjugated
O	308	314	equine
O	315	324	oestrogen
O	325	326	(
O	326	329	CEE
O	329	330	)
O	330	331	,
O	332	334	on
O	335	349	ultrasensitive
O	350	351	C
O	351	352	-
O	352	360	reactive
O	361	368	protein
O	369	374	after
O	375	377	12
O	378	384	months
O	385	387	of
O	388	397	treatment
O	398	400	in
O	401	402	a
O	403	411	retinoid
O	411	412	-
O	412	419	placebo
O	420	430	controlled
O	431	434	two
O	434	435	-
O	435	437	by
O	437	438	-
O	438	441	two
O	442	452	randomized
O	453	459	breast
O	460	466	cancer
O	467	477	prevention
O	478	483	trial
O	484	485	(
O	485	492	Decensi
O	493	494	A
O	495	497	et
O	498	500	al
O	501	502	(
O	502	506	2002
O	506	507	)
O	508	522	Circulation106
O	523	525	10
O	526	530	1224
O	530	531	-
O	531	532	8
O	532	533	)
O	533	534	.

O	535	539	Here
O	539	540	,
O	541	543	we
O	544	555	investigate
O	556	559	the
O	560	567	changes
O	568	570	in
O	571	577	lipids
O	578	581	and
O	582	590	clotting
O	591	598	profile
O	599	601	in
O	602	610	patients
O	611	613	of
O	614	617	the
O	618	622	same
O	623	628	trial
O	628	629	.

O	630	636	Recent
B-eligibility	637	641	post
I-eligibility	641	642	-
I-eligibility	642	652	menopausal
I-eligibility	653	658	women
O	659	663	were
O	664	674	randomised
O	675	677	to
O	678	684	either
O	685	689	oral
O	690	693	CEE
O	694	695	0
O	695	696	.
O	696	699	625
O	700	702	mg
O	702	703	/
O	703	706	day
O	707	710	and
O	711	718	placebo
O	719	720	(
O	720	721	n
O	722	723	=
B-control-participants	724	726	55
O	726	727	)
O	727	728	,
O	729	732	CEE
O	733	736	and
O	737	748	fenretinide
O	749	752	200
O	753	755	mg
O	755	756	/
O	756	759	day
O	760	761	(
O	761	762	n
O	763	764	=
B-intervention-participants	765	767	56
O	767	768	)
O	768	769	,
O	770	781	transdermal
O	782	784	E2
O	785	787	50
O	788	790	mg
O	790	791	/
O	791	794	day
O	795	798	and
O	799	806	placebo
O	807	808	(
O	808	809	n
O	810	811	=
B-control-participants	812	814	59
O	814	815	)
O	816	818	or
O	819	821	E2
O	822	825	and
O	826	837	fenretinide
O	838	841	200
O	842	844	mg
O	844	845	/
O	845	848	day
O	849	850	(
O	850	851	n
O	852	853	=
B-intervention-participants	854	856	56
O	856	857	)
O	857	858	.

O	859	869	Sequential
O	870	889	medroxyprogesterone
O	890	897	acetate
O	898	900	10
O	901	903	mg
O	903	904	/
O	904	907	day
O	908	911	was
O	912	917	given
O	918	920	in
O	921	925	each
O	926	931	group
O	931	932	.

O	933	938	After
O	939	941	12
O	942	948	months
O	948	949	,
O	950	955	there
O	956	959	was
O	960	961	a
O	962	975	statistically
O	976	987	significant
O	988	994	effect
O	995	997	of
O	998	1001	the
O	1002	1007	route
O	1008	1010	of
O	1011	1025	administration
O	1026	1028	of
O	1029	1036	hormone
O	1037	1048	replacement
O	1049	1056	therapy
O	1057	1058	(
O	1058	1061	HRT
O	1061	1062	)
O	1063	1065	on
B-outcome	1066	1076	fibrinogen
I-outcome	1077	1083	levels
O	1083	1084	;
O	1085	1088	the
O	1089	1095	median
O	1096	1106	percentage
O	1107	1113	change
O	1114	1119	being
B-iv-cont-median	1120	1121	-
I-iv-cont-median	1121	1122	5
I-iv-cont-median	1122	1123	.
I-iv-cont-median	1123	1124	7
I-iv-cont-median	1124	1125	%
O	1126	1130	with
O	1131	1134	CEE
O	1135	1138	and
B-iv-cont-median	1139	1140	-
I-iv-cont-median	1140	1141	1
I-iv-cont-median	1141	1142	.
I-iv-cont-median	1142	1143	1
I-iv-cont-median	1143	1144	%
O	1145	1149	with
O	1150	1152	E2
O	1153	1154	(
O	1154	1155	p
O	1156	1157	=
O	1158	1159	0
O	1159	1160	.
O	1160	1163	012
O	1163	1164	)
O	1164	1165	.

B-outcome	1166	1171	Total
I-outcome	1172	1183	cholesterol
O	1184	1193	decreased
O	1194	1196	in
O	1197	1200	all
O	1201	1205	arms
O	1206	1207	(
O	1207	1208	p
O	1209	1210	<
O	1211	1212	0
O	1212	1213	.
O	1213	1217	0001
O	1217	1218	)
O	1218	1219	.

B-outcome	1220	1223	HDL
I-outcome	1223	1224	-
I-outcome	1224	1225	C
O	1226	1235	decreased
O	1236	1249	significantly
O	1250	1254	with
O	1255	1266	transdermal
O	1267	1269	E2
O	1270	1271	(
O	1271	1272	p
O	1273	1274	=
O	1275	1276	0
O	1276	1277	.
O	1277	1280	006
O	1280	1281	)
O	1282	1290	compared
O	1291	1293	to
O	1294	1298	oral
O	1299	1302	CEE
O	1303	1306	and
O	1307	1311	with
O	1312	1323	fenretinide
O	1324	1332	relative
O	1333	1335	to
O	1336	1343	placebo
O	1344	1345	(
O	1345	1346	p
O	1346	1347	<
O	1347	1348	0
O	1348	1349	.
O	1349	1352	001
O	1352	1353	)
O	1353	1354	.

B-outcome	1355	1368	Triglycerides
O	1369	1378	exhibited
O	1379	1381	an
O	1382	1390	opposite
O	1391	1401	modulation
O	1402	1404	in
O	1405	1408	the
O	1409	1412	HRT
O	1413	1418	route
O	1418	1419	,
O	1420	1424	with
O	1425	1426	a
B-iv-cont-median	1427	1429	21
I-iv-cont-median	1429	1430	.
I-iv-cont-median	1430	1431	4
I-iv-cont-median	1431	1432	%
O	1433	1439	median
O	1440	1448	increase
O	1449	1453	with
O	1454	1458	oral
O	1459	1462	CEE
O	1463	1466	and
O	1467	1469	an
B-iv-cont-median	1470	1471	8
I-iv-cont-median	1471	1472	.
I-iv-cont-median	1472	1473	6
I-iv-cont-median	1473	1474	%
O	1475	1484	reduction
O	1485	1489	with
O	1490	1501	transdermal
O	1502	1504	E2
O	1505	1506	(
O	1506	1507	p
O	1508	1509	<
O	1510	1511	0
O	1511	1512	.
O	1512	1516	0001
O	1516	1517	)
O	1517	1518	.

B-outcome	1519	1531	Antithrombin
I-outcome	1531	1532	-
I-outcome	1532	1535	III
O	1536	1542	showed
O	1543	1544	a
O	1545	1546	4
O	1546	1547	%
O	1548	1558	borderline
O	1559	1570	significant
O	1571	1580	reduction
O	1581	1583	in
O	1584	1587	the
O	1588	1599	fenretinide
O	1600	1603	arm
O	1604	1612	relative
O	1613	1615	to
O	1616	1623	placebo
O	1623	1624	,
O	1625	1637	irrespective
O	1638	1640	of
O	1641	1644	the
O	1645	1648	HRT
O	1649	1663	administration
O	1664	1669	route
O	1670	1671	(
O	1671	1672	p
O	1673	1674	=
O	1675	1676	0
O	1676	1677	.
O	1677	1680	055
O	1680	1681	)
O	1681	1682	.

O	1683	1686	Our
O	1687	1691	data
O	1692	1700	indicate
O	1701	1705	that
O	1706	1717	transdermal
O	1718	1720	E2
O	1721	1724	may
O	1725	1727	be
O	1728	1738	preferable
O	1739	1741	to
O	1742	1746	oral
O	1747	1750	CEE
O	1751	1756	based
O	1757	1759	on
O	1760	1763	its
O	1764	1769	safer
O	1770	1784	cardiovascular
O	1785	1789	risk
O	1790	1797	profile
O	1797	1798	.

O	1799	1810	Fenretinide
O	1811	1819	modified
O	1820	1824	some
O	1825	1839	cardiovascular
O	1840	1844	risk
O	1845	1855	biomarkers
O	1856	1859	and
O	1860	1869	confirmed
O	1870	1871	a
O	1872	1877	safer
O	1878	1885	profile
O	1886	1894	compared
O	1895	1897	to
O	1898	1903	other
O	1904	1913	retinoids
O	1913	1914	.
